Impact of intravenous ferric carboxymaltose on physical performance and patient-reported outcomes in elderly patients with non-dialysis CKD, mild anemia, and iron deficiency: A pilot study

Background Iron deficiency (ID) is highly prevalent in chronic kidney disease (CKD) and it's associated with poorer quality of life (QoL) and functional capacity. Intravenous iron therapy is limited to CKD patients with ID and anemia to avoid/delay the need or reduce the dose of erythropoiesis-...

Descripción completa

Detalles Bibliográficos
Autores: Puchades, MJ, Casas, J, Nuñez, J, Gimenez-Civera, E, Gonzales, B, Montomoli, M, de la Espriella, R, Gonzalez-Rico, M, Torregrosa, I, Peña, CJ, Cases, A, Gorriz, JL
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2026
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p20333
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/20333
Access Level:acceso abierto
Palabra clave:Anemia
Iron deficiency
Ferric carboxymaltose
Chronic kidney disease
6-Minute walk test
Quality of life
id ES_8b9d5347c62143c219ef3ce900323e5e
oai_identifier_str oai:fisabio.fundanetsuite.com:p20333
network_acronym_str ES
network_name_str España
repository_id_str
spelling Impact of intravenous ferric carboxymaltose on physical performance and patient-reported outcomes in elderly patients with non-dialysis CKD, mild anemia, and iron deficiency: A pilot studyPuchades, MJCasas, JNuñez, JGimenez-Civera, EGonzales, BMontomoli, Mde la Espriella, RGonzalez-Rico, MTorregrosa, IPeña, CJCases, AGorriz, JLAnemiaIron deficiencyFerric carboxymaltoseChronic kidney disease6-Minute walk testQuality of lifeBackground Iron deficiency (ID) is highly prevalent in chronic kidney disease (CKD) and it's associated with poorer quality of life (QoL) and functional capacity. Intravenous iron therapy is limited to CKD patients with ID and anemia to avoid/delay the need or reduce the dose of erythropoiesis-stimulating agents, according to guidelines. We hypothesized that treatment with IV iron in CKD patients with ID and borderline anemia may improve their physical performance and QoL, independently of its effects on hemoglobin. Methods Prospective, single-arm study in CKD patients with ID and mild anemia. The 6-min walk test (6-MWT), Piper fatigue scale, Patient's global assessment (PGA) and QoL (EQ-5D) questionnaires were evaluated at baseline, and at weeks 1 and 4 after receiving IV ferric carboxymaltose. Changes in continuous endpoints and their longitudinal trajectories were estimated with linear mixed regression models (LMRMs). Results Forty-one patients completed the study. The 6-MWT increased from 296 +/- 101 m to 314 +/- 106 m at week 1 (p < 0.01), and to 325 +/- 111 meters at week 4 (p < 0.01). PGA, EQ-5D questionnaire and Piper Fatigue scale significantly improved at week 4 from baseline (p < 0.05), after adjustment in the last 2 variables. Hemoglobin levels did not increase significantly during the follow-up. Conclusions IV ferric carboxymaltose (IV FCM) was associated with a significant short-term improvement in the 6-MWT in CKD patients with iron deficiency and mild anemia. PGA, EQ-5D and Piper Fatigue Scale also improved at 4 weeks. These findings suggest a potential short-term benefit of IV ferric carboxymaltose on physical performance and PROMs in this population, independent of hemoglobin changes; however, given the small sample size and absence of a control group, results should be interpreted with caution and considered hypothesis-generating.SOC ESPANOLA NEFROLOGIA DR RAFAEL MATESANZ2026info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/20333NEFROLOGIAISSN: 02116995ISSNe: 19892284reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p203332026-06-11T12:45:17Z
dc.title.none.fl_str_mv Impact of intravenous ferric carboxymaltose on physical performance and patient-reported outcomes in elderly patients with non-dialysis CKD, mild anemia, and iron deficiency: A pilot study
title Impact of intravenous ferric carboxymaltose on physical performance and patient-reported outcomes in elderly patients with non-dialysis CKD, mild anemia, and iron deficiency: A pilot study
spellingShingle Impact of intravenous ferric carboxymaltose on physical performance and patient-reported outcomes in elderly patients with non-dialysis CKD, mild anemia, and iron deficiency: A pilot study
Puchades, MJ
Anemia
Iron deficiency
Ferric carboxymaltose
Chronic kidney disease
6-Minute walk test
Quality of life
title_short Impact of intravenous ferric carboxymaltose on physical performance and patient-reported outcomes in elderly patients with non-dialysis CKD, mild anemia, and iron deficiency: A pilot study
title_full Impact of intravenous ferric carboxymaltose on physical performance and patient-reported outcomes in elderly patients with non-dialysis CKD, mild anemia, and iron deficiency: A pilot study
title_fullStr Impact of intravenous ferric carboxymaltose on physical performance and patient-reported outcomes in elderly patients with non-dialysis CKD, mild anemia, and iron deficiency: A pilot study
title_full_unstemmed Impact of intravenous ferric carboxymaltose on physical performance and patient-reported outcomes in elderly patients with non-dialysis CKD, mild anemia, and iron deficiency: A pilot study
title_sort Impact of intravenous ferric carboxymaltose on physical performance and patient-reported outcomes in elderly patients with non-dialysis CKD, mild anemia, and iron deficiency: A pilot study
dc.creator.none.fl_str_mv Puchades, MJ
Casas, J
Nuñez, J
Gimenez-Civera, E
Gonzales, B
Montomoli, M
de la Espriella, R
Gonzalez-Rico, M
Torregrosa, I
Peña, CJ
Cases, A
Gorriz, JL
author Puchades, MJ
author_facet Puchades, MJ
Casas, J
Nuñez, J
Gimenez-Civera, E
Gonzales, B
Montomoli, M
de la Espriella, R
Gonzalez-Rico, M
Torregrosa, I
Peña, CJ
Cases, A
Gorriz, JL
author_role author
author2 Casas, J
Nuñez, J
Gimenez-Civera, E
Gonzales, B
Montomoli, M
de la Espriella, R
Gonzalez-Rico, M
Torregrosa, I
Peña, CJ
Cases, A
Gorriz, JL
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Anemia
Iron deficiency
Ferric carboxymaltose
Chronic kidney disease
6-Minute walk test
Quality of life
topic Anemia
Iron deficiency
Ferric carboxymaltose
Chronic kidney disease
6-Minute walk test
Quality of life
description Background Iron deficiency (ID) is highly prevalent in chronic kidney disease (CKD) and it's associated with poorer quality of life (QoL) and functional capacity. Intravenous iron therapy is limited to CKD patients with ID and anemia to avoid/delay the need or reduce the dose of erythropoiesis-stimulating agents, according to guidelines. We hypothesized that treatment with IV iron in CKD patients with ID and borderline anemia may improve their physical performance and QoL, independently of its effects on hemoglobin. Methods Prospective, single-arm study in CKD patients with ID and mild anemia. The 6-min walk test (6-MWT), Piper fatigue scale, Patient's global assessment (PGA) and QoL (EQ-5D) questionnaires were evaluated at baseline, and at weeks 1 and 4 after receiving IV ferric carboxymaltose. Changes in continuous endpoints and their longitudinal trajectories were estimated with linear mixed regression models (LMRMs). Results Forty-one patients completed the study. The 6-MWT increased from 296 +/- 101 m to 314 +/- 106 m at week 1 (p < 0.01), and to 325 +/- 111 meters at week 4 (p < 0.01). PGA, EQ-5D questionnaire and Piper Fatigue scale significantly improved at week 4 from baseline (p < 0.05), after adjustment in the last 2 variables. Hemoglobin levels did not increase significantly during the follow-up. Conclusions IV ferric carboxymaltose (IV FCM) was associated with a significant short-term improvement in the 6-MWT in CKD patients with iron deficiency and mild anemia. PGA, EQ-5D and Piper Fatigue Scale also improved at 4 weeks. These findings suggest a potential short-term benefit of IV ferric carboxymaltose on physical performance and PROMs in this population, independent of hemoglobin changes; however, given the small sample size and absence of a control group, results should be interpreted with caution and considered hypothesis-generating.
publishDate 2026
dc.date.none.fl_str_mv 2026
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/20333
url https://fisabio.portalinvestigacion.com/publicaciones/20333
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv SOC ESPANOLA NEFROLOGIA DR RAFAEL MATESANZ
publisher.none.fl_str_mv SOC ESPANOLA NEFROLOGIA DR RAFAEL MATESANZ
dc.source.none.fl_str_mv NEFROLOGIA
ISSN: 02116995
ISSNe: 19892284
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869412837351227392
score 15.198674

Similares en LA Referencia